Explore China's bioprocessing needs and capabilities, and tap into the exploding potential of their biologics, biosimilars and vaccines market!
在中国举办生物制程活动原因
即使在全球性经济不景气之中，经济学家们仍然看好2009年中国经济成长率。而支持此一成的支柱即为中国的生物科技领域。强化中国政府的政策或SFDA的指导方针、扩大知识产权、适应GMP・GLP、持续不断地致力于低成本生产，另外丰富的人才库等的贡献也造成中国生物制剂市场持续扩大。中国制药公司一直以来致力于一般医药品、中药或原料药之制造，但是在较先进的制药公司或新兴生物企业之间，也开始有将研究开发新药视为重点的趋势。专利蛋白质、抗体或生物类聚物、还有疫苗等中国许多制药公司的投资组合相继出现。更甚者，欧美医药品业界也认为中国尚属未开发国而相当关注。
现在正是IBC的BioProcess International™ China举办期
BioProcess Internatioanl™ China是以提供中国生物企业及制药公司最前线的生物药剂开发・制造，并培养成为业界主要企业需具备的技术与能力为目的。该活动将提供嘉宾，细胞培养至处方、微生物发酵至净化・回收、分析手法至被称为单一用途／一次性生物制程的价值链，网罗全部领域的主题。会议中，不仅传达业界动向或新型蛋白质・抗体开发、类似药・改良药、治疗用疫苗等的最新动向，也是您针对智能财产、投资或规定之最新数据信息进行会议或小组讨论的场所。
生物制程领域的相关人士，诚挚邀请您参加此活动。共同学习中国的将来发展。
演讲者
Berthold Bödeker, Ph.D.
Head Pilot Plants and Cell Culture
Bayer HealthCare AG
|
Marion F. Gruber, Ph.D.
Associate Director for Regulatory Policy, Center for Biologic Evaluation & Research, Office of Vaccine Research & Review
Food & Drug Administration
|
Geoffrey Allan, Ph.D.
President & CEO
Insmed Incorporated
|
|
Hear late-breaking reports and strategic insights in the plenary sessions focusing on:
- Development and Production of Antibodies and Vaccines in China
- Novel Biotherapeutics Case Studies
- The Business and Regulatory Guidelines for Biosimilars/Follow-on Biologics
- Process Development and Manufacturing Technology
Get up-to-date technical developments and experiences from international companies sharing their expertise on:
- Cell Line Engineering & Development
- Cell Culture
- Analytical Characterization & Quality Control
- Analytical Methods Development
- Purification & Recovery
- Protein Formulation
- Manufacturing Infrastructure & Technology Transfer
- Single Use / Disposables in Manufacturing
Simultaneous translation will be available for the entire conference
|
 |
